期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The impact potential of aflibercept biosimilars
1
作者 Adrienne Delaney Peter K.Kaiser 《Annals of Eye Science》 2025年第1期22-25,共4页
A biologic drug is a medication produced from or containing components of living organisms.Given the rigorous testing that originator biologics undergo to establish Food and Drug Administration(FDA)Biologics License A... A biologic drug is a medication produced from or containing components of living organisms.Given the rigorous testing that originator biologics undergo to establish Food and Drug Administration(FDA)Biologics License Application(BLA)approval,their subsequent price yields a high burden on healthcare systems(1).Biologics account for 37%of prescription drug spending,despite comprising only 2%of all prescribed medications(2).Biosimilar medicines are designed to have active properties that are“highly similar”to a previously licensed reference product,leading to increased chemistry,manufacturing,and controls(CMC). 展开更多
关键词 BIOSIMILAR myl-1701p BIOLOGIC ANTI-VEGF diabetic macular edema(DME)
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部